(S)-2,3,11-trimethoxy-5,8,13,13a-tetrahydro-6H-dibenzo[a,g]quinolizine | 1398120-73-4

• 分子结构分类: 有机化合物 - 生物碱及其衍生物 - 原小檗碱生物碱及其衍生物
• 英文名称: (S)-2,3,11-trimethoxy-5,8,13,13a-tetrahydro-6H-dibenzo[a,g]quinolizine
• 英文别名: (S)-2,3,11-trimethoxytetrahydroprotoberberine；DC037067；(13aS)-2,3,11-trimethoxy-6,8,13,13a-tetrahydro-5H-isoquinolino[2,1-b]isoquinoline
• CAS: 1398120-73-4
• 化学式: C₂₀H₂₃NO₃
• 分子量: 325.408
• InChiKey: HQWHBNSOZIKJSG-SFHVURJKSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  24
• 可旋转键数：
  3
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  30.9
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  3,4-二甲氧基苯甲醛 在 lithium aluminium tetrahydride 、 甲酸 、 (S,S)-N-(对甲苯磺酰)-1,2-二苯乙烷二胺(对异丙基苯)氯化钌(II) 、 ammonium acetate 、 溶剂黄146 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 三乙胺 、 三氯氧磷 作用下， 以 四氢呋喃 、 二氯甲烷 、 N,N-二甲基甲酰胺 、 乙腈 为溶剂， 反应 27.5h， 生成 (S)-2,3,11-trimethoxy-5,8,13,13a-tetrahydro-6H-dibenzo[a,g]quinolizine
  参考文献：
  名称：

  Design, synthesis, and pharmacological evaluation of novel tetrahydroprotoberberine derivatives: Selective inhibitors of dopamine D1 receptor

  摘要：

  A series of new tetrahydroprotoberberine (THPB) derivatives were designed, synthesized, and tested for their binding affinity towards dopamine (D-1 and D-2) and serotonin (5-HT1A and 5-HT2A) receptors. Many of the THPB compounds exhibited high binding affinity and activity at the dopamine D-1 receptor, as well as high selectivity for the D-1 receptor over the D-2, 5-HT1A, and 5-HT2A receptors. Among these, compound 19c exhibited a promising D-1 receptor binding affinity (K-i = 2.53 nM) and remarkable selectivity versus D2R (inhibition = 81.87%), 5-HT1AR (inhibition = 61.70%), and 5-HT2AR (inhibition = 24.96%). Compared with l-(S)-stepholidine (l-SPD) (D-1 K-i = 6.23 nM, D-2 K-i = 56.17 nM), compound 19c showed better binding affinity for the D-1 receptor (2.5-fold higher) and excellent D-2/D-1 selectivity. Functional assays found compounds 18j, 18k, and 19c are pure D-1 receptor antagonists. These results indicate that removing the C10 hydroxy group and introducing a methoxy group at C11 of the pharmacophore of l-SPD can reverse the function of THPB compounds at the D-1 receptor. These results are in accord with molecular docking studies. Crown Copyright (C) 2012 Published by Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2012.05.057

文献信息

• HEXAHYDRODIBENZO[A,G]QUINOLIZINE COMPOUND, PREPARATION METHOD THEREOF, PHARMACEUTICAL COMPOSITION AND USE THEREOF
  申请人：Shanghai Institute of Materia Medica, Chinese Academy of Sciences

  公开号：US20140088130A1

  公开（公告）日：2014-03-27

  The present invention relates to a novel hexahydrodibenzo[a,g]quinoline compound represented by general formula (I) and its derivatives, enantiomer, diastereoisomer, raceme and mixtures thereof, as well as pharmaceutically acceptable salts thereof. The present invention further relates to a method for preparing the compound, and the compound has good prevention and treatment effect on neurological diseases, especially diseases associated with dopamine receptor and 5-hydroxytryptamine receptor. The bioactivity experiment demonstrates that, the compound is expected to be developed into a novel and potent chemical entity for treating diseases associated with dopamine receptor and 5-hydroxytryptamine receptor, especially schizophrenia, Parkinson's disease, drug addiction, migraine and so on.

  本发明涉及一种由通式（I）表示的新型六氢二苯并[a,g]喹啉化合物及其衍生物、对映体、非对映体异构体、混合物以及其药学上可接受的盐。本发明还涉及一种制备该化合物的方法，该化合物对神经系统疾病具有良好的预防和治疗效果，特别是与多巴胺受体和5-羟色胺受体相关的疾病。生物活性实验证明，该化合物有望被开发成一种新型和有效的化学实体，用于治疗与多巴胺受体和5-羟色胺受体相关的疾病，特别是精神分裂症、帕金森病、药物成瘾、偏头痛等疾病。
• [EN] HEXAHYDRODIBENZO[A,G]QUINOLIZINE COMPOUND, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION AND USE THEREOF<br/>[FR] COMPOSÉ D'HEXAHYDRODIBENZO[A,G]QUINOLIZINE, SON PROCÉDÉ DE PRÉPARATION, COMPOSITION PHARMACEUTIQUE ET SON UTILISATION
  申请人：SHANGHAI INST MATERIA MEDICA

  公开号：WO2012163179A1

  公开（公告）日：2012-12-06

  发明涉及一种具有通式(I)所示的新颖的六氢二苯并[a,g]喹嗪类化合物及其衍生物，其对映异构体、非对映异构体、外消旋体及其混合物，及其药学上可接受的盐。本发明还涉及该类化合物的制备方法，另外该类化合物对神经系统疾病，特别是与多巴胺受体和五羟色胺受体相关的疾病有较好的防治作用。生物学活性实验表明，该类化合物有望开发成为一类治疗与多巴胺受体及五羟色胺受体相关的疾病特别是精神分裂症、帕金森氏症、药物成瘾性、偏头痛等疾病的强效的新化学实体。
• US9359372B2
  申请人：——

  公开号：US9359372B2

  公开（公告）日：2016-06-07
• Design, synthesis, and pharmacological evaluation of novel tetrahydroprotoberberine derivatives: Selective inhibitors of dopamine D1 receptor
  作者：Wangke Qian、Weijian Lu、Haifeng Sun、Zeng Li、Liyuan Zhu、Rui Zhao、Lei Zhang、Shengbin Zhou、Yu Zhou、Hualiang Jiang、Xuechu Zhen、Hong Liu

  DOI：10.1016/j.bmc.2012.05.057

  日期：2012.8

  A series of new tetrahydroprotoberberine (THPB) derivatives were designed, synthesized, and tested for their binding affinity towards dopamine (D-1 and D-2) and serotonin (5-HT1A and 5-HT2A) receptors. Many of the THPB compounds exhibited high binding affinity and activity at the dopamine D-1 receptor, as well as high selectivity for the D-1 receptor over the D-2, 5-HT1A, and 5-HT2A receptors. Among these, compound 19c exhibited a promising D-1 receptor binding affinity (K-i = 2.53 nM) and remarkable selectivity versus D2R (inhibition = 81.87%), 5-HT1AR (inhibition = 61.70%), and 5-HT2AR (inhibition = 24.96%). Compared with l-(S)-stepholidine (l-SPD) (D-1 K-i = 6.23 nM, D-2 K-i = 56.17 nM), compound 19c showed better binding affinity for the D-1 receptor (2.5-fold higher) and excellent D-2/D-1 selectivity. Functional assays found compounds 18j, 18k, and 19c are pure D-1 receptor antagonists. These results indicate that removing the C10 hydroxy group and introducing a methoxy group at C11 of the pharmacophore of l-SPD can reverse the function of THPB compounds at the D-1 receptor. These results are in accord with molecular docking studies. Crown Copyright (C) 2012 Published by Elsevier Ltd. All rights reserved.